OneTox

Product Overview

ONE TOX is a South Korean botulinum toxin type A product from the JDBIO portfolio. Available in ONE TOX 100 Units and ONE TOX 200 Units, the formulation contains Clostridium botulinum toxin type A, human serum albumin, and sodium chloride. Both strengths are supplied as lyophilized powder in transparent glass vials and require refrigerated storage. ONE TOX is commercially positioned for professional medical aesthetics applications involving temporary modulation of muscle activity.

The product is associated with JDBIO Co., Ltd., a South Korean medical aesthetics company offering botulinum toxin products, hyaluronic acid dermal fillers, and other professional aesthetic solutions.

The two ONE TOX formulations contain the same declared ingredients but differ in their total biological potency and excipient quantities. ONE TOX 100U contains 100 Units of botulinum toxin type A, while ONE TOX 200U contains 200 Units.

JDBIO identifies ONE TOX as a botulinum toxin product designed to temporarily reduce neuromuscular signaling. The product's pharmacological mechanism is associated with inhibition of acetylcholine release at peripheral cholinergic nerve terminals.

This TEOSQUARE product page covers ONE TOX 100U and 200U, providing professional buyers with information about composition, vial strengths, packaging, storage requirements, pharmacological characteristics, and regulatory considerations.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A, a neuromodulating protein that temporarily inhibits acetylcholine release at susceptible nerve terminals.
• 100U and 200U Formulations: Available in two strengths containing 100 or 200 Units of product-specific biological potency per vial.
• Albumin-Containing Formulation: Includes human serum albumin and sodium chloride as pharmaceutical excipients, with quantities corresponding to the selected vial strength.
• Lyophilized Powder: Supplied as white to pale-yellow dried material in a transparent glass vial.
• South Korean Product: Part of the JDBIO product portfolio, with both 100U and 200U presentations documented in the company's commercial catalogue.

Composition & Specifications

ONE TOX contains Clostridium botulinum toxin type A as its principal active ingredient. Human serum albumin and sodium chloride are included as supporting pharmaceutical excipients.

The two formulations contain different total quantities of these ingredients, corresponding to their labeled strengths.

Clostridium Botulinum Toxin Type A

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum.

In pharmaceutical preparations, botulinum toxin type A temporarily inhibits neurotransmitter release at susceptible peripheral nerve terminals.

Its principal pharmacological effect involves reducing the release of acetylcholine, a neurotransmitter essential for communication between motor neurons and skeletal muscle fibers.

ONE TOX is available in two documented strengths:

• ONE TOX 100U: Contains 100 Units of Clostridium botulinum toxin type A per vial.
• ONE TOX 200U: Contains 200 Units of Clostridium botulinum toxin type A per vial.

Botulinum toxin potency is expressed in biological activity units rather than as a physical mass of active protein.

These units are associated with product-specific biological potency testing and must not automatically be considered equivalent between different commercial botulinum toxin products.

Human Serum Albumin

Human serum albumin is a plasma-derived protein used as a stabilizing excipient in certain biological pharmaceutical formulations.

Albumin can contribute to protein stability during manufacturing, storage, and handling.

ONE TOX 100U contains 0.5 mg human serum albumin, while ONE TOX 200U contains 1.0 mg.

Human serum albumin is not the principal neuromodulating ingredient. Its role is associated with formulation stability rather than direct inhibition of neurotransmitter release.

Because albumin is derived from human biological material, appropriate manufacturing controls and product-specific safety information remain important.

Sodium Chloride

Sodium chloride is a pharmaceutical excipient widely used in injectable preparations.

It contributes to the physicochemical characteristics of the formulation.

ONE TOX 100U contains 0.9 mg sodium chloride per vial, while ONE TOX 200U contains 1.8 mg.

These quantities refer to the original dried product and should not be confused with the composition of any separately supplied preparation solution.

The ingredient quantities are based on the published ONE TOX product specifications. The exact formulation, pharmaceutical registration, and responsible legal manufacturing entity should be confirmed from the original product labeling and manufacturer-issued documentation.

How ONE TOX Botulinum Toxin Type A Works

ONE TOX contains botulinum toxin type A, which temporarily inhibits acetylcholine release at susceptible peripheral cholinergic nerve terminals.

This mechanism reduces neuromuscular transmission and produces temporary relaxation or weakness of affected skeletal muscles.

Normal Neuromuscular Transmission

Under normal physiological conditions, motor neurons release acetylcholine at the neuromuscular junction.

Acetylcholine binds to receptors on skeletal muscle cells, initiating the electrical processes that lead to muscle contraction.

Neurotransmitter release depends on specialized proteins responsible for the fusion of acetylcholine-containing vesicles with the nerve-terminal membrane.

SNAP-25 Cleavage

Botulinum toxin type A contains an enzymatically active light chain that cleaves SNAP-25.

SNAP-25 is a protein involved in the SNARE complex, which is essential for the fusion of neurotransmitter-containing vesicles.

Cleavage of SNAP-25 interferes with the release of acetylcholine from susceptible nerve terminals.

This reduces the transmission of electrical signals from motor neurons to affected skeletal muscles.

Temporary Muscle Relaxation

Reduced acetylcholine release temporarily decreases neuromuscular signaling and muscle contraction.

In authorized aesthetic applications, botulinum toxin type A may temporarily improve the appearance of dynamic facial wrinkles associated with repeated muscle activity.

Dynamic wrinkles are facial lines that become more visible during expressions such as frowning, smiling, or raising the eyebrows.

JDBIO commercially positions ONE TOX for the temporary improvement of facial expression wrinkles, particularly glabellar lines.

However, commercial positioning does not independently establish an approved indication in every country.

Recovery of Neuromuscular Function

The pharmacological effects of botulinum toxin type A are temporary.

Neuromuscular function can gradually recover through biological processes involving nerve-terminal recovery and restoration of neurotransmitter release.

The onset, magnitude, and duration of clinical effects depend on the finished formulation, administration conditions, patient characteristics, and authorized indication.

A specific duration of action should not be guaranteed for ONE TOX solely from general studies involving other botulinum toxin products.

These mechanisms are established for botulinum toxin type A. They do not demonstrate interchangeable potency, identical clinical performance, or equivalent safety between ONE TOX and other commercial botulinum toxin products.

Available ONE TOX Variants

ONE TOX is available in two strengths: ONE TOX 100 Units and ONE TOX 200 Units.

Both formulations contain Clostridium botulinum toxin type A, human serum albumin, and sodium chloride.

Their principal differences are the total labeled biological potency and excipient quantities contained in each vial.

ONE TOX 100 Units

ONE TOX 100U contains 100 Units of Clostridium botulinum toxin type A per vial.

The formulation includes 0.5 mg human serum albumin and 0.9 mg sodium chloride.

It is supplied as white to pale-yellow lyophilized material in a transparent glass vial.

JDBIO documents ONE TOX 100U as a medicinal product intended for professional applications involving temporary modulation of muscle activity.

The company identifies temporary improvement of moderate to severe glabellar wrinkles among the product's commercial applications.

ONE TOX 100U is documented as an individual vial presentation, while the JDBIO commercial catalogue also identifies a ten-vial carton configuration.

ONE TOX 200 Units

ONE TOX 200U is the higher-strength presentation within the product family.

Each vial contains 200 Units of Clostridium botulinum toxin type A, 1.0 mg human serum albumin, and 1.8 mg sodium chloride.

The product contains twice the total labeled biological potency of ONE TOX 100U.

This does not mean that each individual unit has greater potency or that the product necessarily produces stronger or longer-lasting clinical effects.

ONE TOX 200U is also supplied as a lyophilized preparation in a glass vial.

JDBIO documents the 200U product as an individual vial presentation and identifies a ten-vial carton configuration in its product catalogue.

The differences between ONE TOX 100U and 200U are their total labeled potency and excipient quantities. The 200U presentation should not be interpreted as a different botulinum toxin serotype or as evidence of greater potency per individual unit.

Packaging & Product Presentation

ONE TOX 100U and 200U are supplied as lyophilized powder in transparent glass vials.

Both strengths are documented by JDBIO as individual vial products.

The company's commercial catalogue also identifies ten-vial carton configurations for both formulations.

The labeled potency represents the total biological activity contained in each original vial.

It does not represent a liquid volume or recommended administration quantity.

Buyers should verify whether their selected purchasing option contains an individual vial or a larger carton.

Product identification should include the original brand name, labeled potency, batch number, expiration date, responsible legal manufacturer, and applicable market-specific pharmaceutical labeling.

The documented ten-vial carton is a commercial packaging configuration and does not establish that all distributors sell ONE TOX exclusively in ten-vial quantities.

Storage & Handling

JDBIO specifies refrigerated storage at 2°C to 8°C for ONE TOX 100U. The same refrigerated range is identified in published commercial information for ONE TOX 200U.

Both products should be handled according to the original manufacturer-issued labeling applicable to the supplied formulation.

• Refrigerated Storage: Store unopened vials at 2°C to 8°C according to the documented product specifications.
• Temperature-Controlled Distribution: Maintain appropriate refrigerated conditions during storage and transportation.
• Original Packaging: Keep the product in its original sealed vial and manufacturer packaging.
• Container Integrity: Inspect the vial and packaging for damage or evidence of compromised integrity.
• Product Traceability: Confirm the labeled strength, batch number, expiration date, and manufacturer information.
• Professional Handling: Follow the product-specific instructions for preparation, administration, and disposal.

Shelf Life

JDBIO documents a shelf life of 36 months for ONE TOX 100U under the stated storage conditions.

The same shelf life is reported for ONE TOX 200U by commercial suppliers, but the definitive specification should be confirmed from the original 200U product labeling.

Storage and handling requirements after preparation may differ from those applicable to an unopened lyophilized vial.

The original manufacturer labeling takes precedence over distributor information. Storage conditions for ONE TOX should not automatically be substituted with those of other botulinum toxin products.

Safety & Regulatory Considerations

ONE TOX contains botulinum toxin type A, a potent neuroactive substance. Any clinical application requires appropriate medical supervision and compliance with the product's applicable regulatory authorization.

Potential Adverse Reactions

Adverse reactions associated with botulinum toxin type A products may include localized discomfort, redness, swelling, bruising, headache, and unintended weakness of nearby muscles.

Depending on the circumstances of administration, additional complications may include eyelid ptosis, facial asymmetry, or other functional changes.

These are recognized risks associated with the pharmacological class. Their specific incidence for ONE TOX has not been independently established from publicly available product-specific clinical evidence.

Potential Spread of Toxin Effects

Botulinum toxin products can cause serious complications if their effects spread beyond the intended administration area.

Potential systemic effects include generalized muscle weakness, swallowing difficulties, speech disturbances, and respiratory impairment.

Such complications can be life-threatening and require immediate medical evaluation.

Contraindications and Precautions

Known hypersensitivity to botulinum toxin type A or relevant formulation components and infection at the intended administration site are important considerations for this category of medicines.

Certain neuromuscular disorders and medications affecting neuromuscular transmission may increase the risk of adverse reactions.

ONE TOX contains human serum albumin, making the safety considerations associated with human-derived biological excipients relevant to product evaluation.

Non-Interchangeable Potency Units

Botulinum toxin biological potency units are product-specific.

ONE TOX units should not be directly converted into equivalent quantities of BOTOX, Dysport, Xeomin, NABOTA, or other commercial botulinum toxin preparations.

Similar numerical unit counts do not establish identical clinical efficacy, treatment duration, diffusion characteristics, or safety.

Clinical Evidence Limitations

JDBIO commercially describes ONE TOX as a botulinum toxin type A formulation associated with temporary improvement of facial expression wrinkles.

However, the publicly available product information reviewed for this page does not establish completed, independently verified clinical trials demonstrating a specific onset time, duration, or comparative superiority for both ONE TOX strengths.

Clinical findings involving other botulinum toxin type A products should not automatically be attributed to ONE TOX.

Regulatory Authorization

ONE TOX is identified as a South Korean botulinum toxin type A medicinal product in JDBIO's commercial documentation.

However, the current product-specific marketing authorization, approved prescribing information, and legal manufacturing entity have not been independently established for every destination market.

US FDA approval for ONE TOX 100U or ONE TOX 200U has not been established.

Regulatory authorization granted to another botulinum toxin type A product does not automatically apply to ONE TOX.

Buyers should verify the exact product's pharmaceutical registration, approved indications, import eligibility, prescription requirements, responsible manufacturer, and lawful distribution status before procurement.

This information is intended for professional product identification and commercial evaluation. It does not establish approved clinical indications, provide preparation or administration instructions, replace official prescribing information, or authorize distribution outside applicable pharmaceutical regulations.

Frequently Asked Questions